Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.
Clinical Trials
15
5 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2018
Active, not recruiting
5
33.3%
Completed
1
6.7%
Recruiting
6
40.0%
Terminated
3
20.0%
No approval data available
- Jefferies analysts identify neuroinflammation as one of the most important emerging storylines in Parkinson's disease drug development, with key milestones expected heading into 2027. - The addressable early Parkinson's population across the US and EU is projected to exceed two million patients by 2035, representing a potential disease-modifying therapy market approaching $8 billion. - BioVie's bezisterim reported positive Phase 2 topline data showing improvements in blood-based inflammatory markers and clinical outcomes, with patients having higher baseline inflammation seeing the greatest benefit. - Jefferies contends that Parkinson's is driven by multiple mechanisms—alpha-synuclein, cellular cleanup breakdown, and neuroinflammation—meaning single-pathway drugs alone are unlikely to succeed.
- Eli Lilly announced a definitive agreement to acquire UK-based Centessa Pharmaceuticals for up to $7.8 billion, marking the company's strategic expansion into sleep medicine and neurological disorders. - Centessa's lead candidate cleminorexton has demonstrated potential best-in-class profile in Phase 2a studies across narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia through its orexin receptor 2 agonist mechanism. - The acquisition includes $38 per share in cash plus contingent value rights worth up to $9 per share, with payments tied to FDA approvals for narcolepsy and idiopathic hypersomnia treatments. - The deal represents Lilly's continued diversification beyond its metabolic portfolio, following recent acquisitions of Orna Therapeutics for $2.4 billion and Ventyx Biosciences for over $1 billion.
- Ventyx Biosciences has expanded its Phase 2 trial of VTX2735 for recurrent pericarditis into Canada, EU, and the UK to evaluate once-daily dosing in preparation for global Phase 3 development. - The company added Mark McKenna, former CEO of Prometheus Biosciences, and cardiovascular specialist Dr. Peter Libby to its advisory board to guide strategic decisions for its NLRP3 inhibitor portfolio. - Interim analysis data from the ongoing Phase 2 recurrent pericarditis study will be presented at Ventyx's R&D Day planned for Q1 2026, representing a modest delay from prior guidance. - The current Phase 2 study is evaluating VTX2735 at 150 mg twice daily with primary endpoints measured at week 6, including safety, pain scores, and inflammatory markers.
- Ventyx Biosciences' Phase II trial of VTX3232 demonstrated a 78% reduction in hsCRP levels compared to a 3% increase in the placebo group, indicating significant anti-inflammatory effects. - The oral, once-daily therapy also showed substantial decreases in other inflammatory markers including IL-6, Lp(a), fibrinogen, and ESR in patients with obesity and cardiovascular risk factors. - VTX3232 demonstrated potential as both monotherapy and in combination with semaglutide, with the combination showing significant reductions in liver inflammation. - The positive results have driven a 468.97% increase in stock price over six months and prompted analysts to maintain Buy ratings with price targets up to $21.
- Ventyx Biosciences' experimental oral therapy VTX3232 demonstrated an 80% reduction in hsCRP inflammation markers within one week in a 175-patient Phase 2 trial targeting cardiovascular disease risk. - The NLRP3 inflammasome inhibitor achieved significant reductions in multiple cardiovascular risk factors including IL-6, lipoprotein(a), and fibrinogen, with 69% of patients reaching target hsCRP levels below 2mg/L. - Company shares surged over 105% following the announcement, reaching $7.82 as Wall Street analysts maintain a "Strong Buy" consensus with an average price target of $13.75. - While VTX3232 failed to produce weight loss effects when used alone or with semaglutide, the cardiovascular inflammation results position it as a potential breakthrough therapy for heart disease prevention.
- Phase 2 trial of VTX958, an oral TYK2 inhibitor, demonstrated significant endoscopic improvement in Crohn's disease patients, with up to 32.4% achieving endoscopic response at Week 12. - While the trial missed its primary CDAI endpoint due to high placebo response, VTX958 showed robust dose-dependent improvements in objective measures including endoscopic scores and inflammatory biomarkers. - The drug maintained a favorable safety profile, supporting its potential as a novel oral therapy option for Crohn's disease patients, with ongoing analysis of 52-week extension data to inform future development.
- Ventyx Biosciences presented extended Phase 2 trial results for tamuzimod (VTX002) at UEG Week 2024, demonstrating sustained efficacy in ulcerative colitis treatment over 52 weeks. - The S1P1R modulator showed potential best-in-class safety profile among oral ulcerative colitis therapies, with high rates of clinical and endoscopic remission observed. - Researchers suggest tamuzimod could serve as a foundation for future combination therapies in ulcerative colitis treatment, marking a significant advancement in oral immunology therapeutics.
- Ventyx Biosciences initiated a Phase 2 trial of VTX3232 for obesity and cardiometabolic risk factors, with topline data expected in the second half of 2025. - A Phase 2 trial of VTX2735 for recurrent pericarditis is expected to begin in January, with topline results anticipated in the second half of 2025. - Topline data from an ongoing Phase 2 biomarker trial of VTX3232 in early Parkinson’s disease are expected in the first half of 2025.
• The NLRP3 protein inhibitors pipeline is robust, with over 20 companies developing more than 25 inhibitors targeting various inflammatory conditions. • NLRP3 inhibitors are being explored for treating neurodegenerative diseases like Alzheimer’s and Parkinson’s, as well as metabolic conditions such as NASH. • Clinical trials are underway, with companies like Novo Nordisk and NodThera reporting positive data on their NLRP3 inhibitor candidates. • Collaborations, such as the one between Halia Therapeutics and Biolexis Therapeutics, are advancing the development of brain-penetrant NLRP3 inhibitors for neuroinflammation.
- Ventyx Biosciences advances VTX3232 into Phase 2 trials for early Parkinson's and obesity, expecting topline results in H1 and H2 2025, respectively. - Tonix Pharmaceuticals submitted an NDA for TNX-102 SL for fibromyalgia, with a potential FDA decision expected in December 2024. - Tonix Pharmaceuticals secured a DoD contract worth up to $34 million for antiviral drug development and reported Q3 2024 product revenue of $2.8 million. - Ventyx Biosciences reported a cash balance of $274.8 million, expected to fund operations into at least H2 2026, while Tonix Pharmaceuticals reported $28.2 million in cash.
